But when your peripheral nerves-those found outside of the brain and spinal cord-are damaged, it can cause pain and numbness ...

If approved by the EC, Wainzua would be the only approved medicine for the treatment of ATTRv-PN in the EU able to be self-administered with an autoinjector on a monthly basis. “Due to the progressive ...

Alnylam Pharmaceuticals ALNY presented new data from its early-stage study of nucresiran (formerly ALN-TTRsc04) for treating ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

The Extreme Team often works with Veterans Community Response (VCR), including Travis Alexander. Alexander, VCR team leader ...

for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. “Today marks another important milestone in our journey to ...

Having additional amyloidosis treatment options designed to reduce the production ... “Due to the progressive nature of polyneuropathy of hereditary transthyretin-mediated amyloidosis, it is critical ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

(Alliance News) - AstraZeneca PLC on Monday said its Wainzua treatment has been been recommended for EU approval to treat adult patients with polyneuropathy associated with hereditary ...